Literature DB >> 1712105

Identification of type-specific linear epitopes in the glycoproteins gp46 and gp21 of human T-cell leukemia viruses type I and type II using synthetic peptides.

P Horal1, W W Hall, B Svennerholm, J Lycke, S Jeansson, L Rymo, M H Kaplan, A Vahlne.   

Abstract

Synthetic peptides of 20-25 amino acids were employed in enzyme-linked immunosorbent assays to identify linear epitopes in the external glycoprotein gp46 and the transmembrane glycoprotein gp21 of human T-cell leukemia/lymphotropic viruses type I (HTLV-I) and II (HTLV-II). Ten linear epitopes were identified in the HTLV-I glycoproteins, seven in gp46 and three in gp21. Three major linear epitopes were identified in the gp46 of HTLV-II. Peptides representing linear epitopes of gp46 were found to be sensitive and specific for the detection of antibody and permit serological identification and differentiation of HTLV-I and HTLV-II infections.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1712105      PMCID: PMC51956          DOI: 10.1073/pnas.88.13.5754

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  High rate of HTLV-II infection in seropositive i.v. drug abusers in New Orleans.

Authors:  H Lee; P Swanson; V S Shorty; J A Zack; J D Rosenblatt; I S Chen
Journal:  Science       Date:  1989-04-28       Impact factor: 47.728

2.  Integrated human T-cell leukemia virus II genome in CD8 + T cells from a patient with "atypical" hairy cell leukemia: evidence for distinct T and B cell lymphoproliferative disorders.

Authors:  J D Rosenblatt; J V Giorgi; D W Golde; J B Ezra; A Wu; C D Winberg; J Glaspy; W Wachsman; I S Chen
Journal:  Blood       Date:  1988-02       Impact factor: 22.113

3.  A second isolate of HTLV-II associated with atypical hairy-cell leukemia.

Authors:  J D Rosenblatt; D W Golde; W Wachsman; J V Giorgi; A Jacobs; G M Schmidt; S Quan; J C Gasson; I S Chen
Journal:  N Engl J Med       Date:  1986-08-07       Impact factor: 91.245

4.  HTLV-I associated myelopathy, a new clinical entity.

Authors:  M Osame; K Usuku; S Izumo; N Ijichi; H Amitani; A Igata; M Matsumoto; M Tara
Journal:  Lancet       Date:  1986-05-03       Impact factor: 79.321

5.  Discrimination between antibodies to HIV and to related retroviruses using site-directed serology.

Authors:  E Norrby; G Biberfeld; F Chiodi; A von Gegerfeldt; A Nauclér; E Parks; R Lerner
Journal:  Nature       Date:  1987 Sep 17-23       Impact factor: 49.962

6.  Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis.

Authors:  A Gessain; F Barin; J C Vernant; O Gout; L Maurs; A Calender; G de Thé
Journal:  Lancet       Date:  1985-08-24       Impact factor: 79.321

7.  A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia.

Authors:  V S Kalyanaraman; M G Sarngadharan; M Robert-Guroff; I Miyoshi; D Golde; R C Gallo
Journal:  Science       Date:  1982-11-05       Impact factor: 47.728

8.  Seroprevalence and epidemiological correlates of HTLV-I infection in U.S. blood donors.

Authors:  A E Williams; C T Fang; D J Slamon; B J Poiesz; S G Sandler; W F Darr; G Shulman; E I McGowan; D K Douglas; R J Bowman
Journal:  Science       Date:  1988-04-29       Impact factor: 47.728

9.  Type-specific antigens for serological discrimination of HTLV-I and HTLV-II infection.

Authors:  Y M Chen; T H Lee; S Z Wiktor; G M Shaw; E L Murphy; W A Blattner; M Essex
Journal:  Lancet       Date:  1990-11-10       Impact factor: 79.321

10.  Prevalence of human T-cell leukemia/lymphoma virus (HTLV) type II infection among high-risk individuals: type-specific identification of HTLVs by polymerase chain reaction.

Authors:  G D Ehrlich; J B Glaser; K LaVigne; D Quan; D Mildvan; J J Sninsky; S Kwok; L Papsidero; B J Poiesz
Journal:  Blood       Date:  1989-10       Impact factor: 22.113

View more
  27 in total

1.  Neutralizing human monoclonal antibodies to conformational epitopes of human T-cell lymphotropic virus type 1 and 2 gp46.

Authors:  K G Hadlock; J Rowe; S Perkins; P Bradshaw; G Y Song; C Cheng; J Yang; R Gascon; J Halmos; S M Rehman; M S McGrath; S K Foung
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Glycine-amide is an active metabolite of the antiretroviral tripeptide glycyl-prolyl-glycine-amide.

Authors:  Elin Andersson; Peter Horal; Alenka Jejcic; Stefan Höglund; Jan Balzarini; Anders Vahlne; Bo Svennerholm
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

3.  Identification of group-common linear epitopes in structural and nonstructural proteins of enteroviruses by using synthetic peptides.

Authors:  J Cello; A Samuelson; P Stålhandske; B Svennerholm; S Jeansson; M Forsgren
Journal:  J Clin Microbiol       Date:  1993-04       Impact factor: 5.948

4.  Detection of antibodies to hepatitis C virus (HCV) structural proteins in anti-HCV-positive sera by an enzyme-linked immunosorbent assay using synthetic peptides as antigens.

Authors:  C Ishida; K Matsumoto; K Fukada; K Matsushita; H Shiraki; Y Maeda
Journal:  J Clin Microbiol       Date:  1993-04       Impact factor: 5.948

5.  Identification of functional regions in the human T-cell leukemia virus type I SU glycoprotein.

Authors:  L Delamarre; C Pique; D Pham; T Tursz; M C Dokhélar
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

6.  GPG-NH2 acts via the metabolite alphaHGA to target HIV-1 Env to the ER-associated protein degradation pathway.

Authors:  Alenka Jejcic; Stefan Höglund; Anders Vahlne
Journal:  Retrovirology       Date:  2010-03-15       Impact factor: 4.602

7.  Synthetic peptide-based immunoassays for distinguishing between human T-cell lymphotropic virus type I and type II infections in seropositive individuals.

Authors:  R B Lal; W Heneine; D L Rudolph; W B Present; D Hofhienz; T M Hartley; R F Khabbaz; J E Kaplan
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

8.  Identification and characterization of an extended Tax protein in human T-cell lymphotropic virus type II subtype b isolates.

Authors:  D Pardi; J E Kaplan; J E Coligan; T M Folks; R B Lal
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

9.  The humoral immune response to human T-cell lymphotropic virus type 1 envelope glycoprotein gp46 is directed primarily against conformational epitopes.

Authors:  K G Hadlock; J Rowe; S K Foung
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

10.  Isolation of a human T-lymphotropic virus type I strain from Australian aboriginals.

Authors:  I Bastian; J Gardner; D Webb; I Gardner
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.